Chase Coleman III
Tiger Global Management
Chase Coleman III Ginkgo Bioworks Holdings stake
total: 436
Tiger Global Management DNA trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q3
- Held for:
- 2 quarters
- Latest activity:
- 2022 Q1
According to 2026 Q2 report, Chase Coleman III doesn't hold any Ginkgo Bioworks Holdings (DNA) shares. To date, the estimated cost basis is nearly $11.59 for "buy" trades and estimated average "sell" price is $8.31. Tiger Global Management first purchased DNA in 2021 Q3, initially acquiring about 2.42M shares. Since the initial investment in Ginkgo Bioworks Holdings (DNA), Tiger Global Management has made 1 more transaction.
When did Chase Coleman III sell Ginkgo Bioworks Holdings (DNA)?
Chase Coleman III sold off the entire Ginkgo Bioworks Holdings (DNA) position in 2022 Q1.
When did Chase Coleman III buy Ginkgo Bioworks Holdings (DNA)?
Chase Coleman III first invested in Ginkgo Bioworks Holdings (DNA) in 2021 Q3 at the reported quarter-end price of $11.59 per share.
What's the cost basis of Tiger Global Management's DNA stake?
The estimated cost basis for Ginkgo Bioworks Holdings (DNA) stake is around $11.59 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $11.59
- Weighted AVG sell price:
- $8.31
Chase Coleman III's historical trades in Ginkgo Bioworks Holdings
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q1
|
0.00%
|
0
|
$8.31
|
|
-100% (-2,425,000)
|
-0.04%
|
|
2021 Q3
|
0.05%
|
2,425,000
|
$11.59
|
$28,106,000
|
new
|
+0.05%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.